Brief: Northstrive Biosciences plans meeting with FDA for its new obesity reducing therapy
10/03/2025 15:15
March 10 (Reuters) - PMGC Holdings Inc ELAB.O: NORTHSTRIVE BIOSCIENCES INC. SCHEDULES PRE-IND MEETING WITH FDA FOR EL-22, AN OBESITY THERAPY TARGETING FAT LOSS AND MUSCLE PRESERVATION IN COMBINATION WITH GLP-1 NORTHSTRIVE BIOSCIENCES : SCHEDULED A PRE-IND MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION FOR APRIL 23, 2025 Source text: nGNX7B0PkG Further company coverage: ELAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PMGC Holdings
See all newsBrief: PMGC Announces DBA As NorthStrive Holdings Trademark License Agreement, & Website Update
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
Pmgc Holdings Rises As Unit Expands Rights To Ai: discovered obesity, heart disease drug program